Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1998 September;40(3) > Panminerva Medica 1998 September;40(3):186-90





Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1998 September;40(3):186-90

lingua: Inglese

Study of ­release of eosin­o­phil cat­ion­ic pro­teins (ECP and EPX) in the hyper­eo­sin­o­phil­ic syn­drome (HES) and oth­er hyper­eo­sin­o­phil­ic con­di­tions

Bobbio-Pallavicini E.*, Confalonieri M.**, Tacconi F.*, Mainardi E.*, Della Porta R.***, Ceccato D.°, Maccario R.°, De Amici M.°

From the * Divi­sion of Gen­er­al Med­i­cine and ** Divi­sion of Pneu­mol­o­gy Ospe­dale Mag­giore, Cre­ma
***Divi­sion of Gen­er­al Med­i­cine Cor­te­mag­giore Hos­pi­tal
°Insti­tute of Pedi­at­ric Clin­ic, IRCCS San Mat­teo Poly­clin­ic Uni­ver­sity of ­Pavia, ­Pavia, Ita­ly


Back­ground. Up to ­date, the eti­ol­o­gy and the path­o­gen­e­sis of HES are ­still ­unknown and par­tic­u­lar­ly it is ­unclear why eosin­o­phils in HES are ­more aggres­sive ­towards tis­sues ­than in oth­er eosin­o­phil­ic con­di­tions.
Meth­ods. We ­assessed the cat­ion­ic pro­teins ECP and EPX ser­um con­cen­tra­tions, ­their in ­vitro ­release ­from poly­mor­pho­nu­cle­ar ­cell cul­ture, and the mono­clo­nal anti­bod­ies EG1 and EG2 in 3 ­patients ­with HES, 6 ­patients ­with oth­er hyper­eo­sin­o­phil­ic con­di­tions and 20 ­healthy con­trol sub­jects.
­Results. Ser­um ECP and EPX con­cen­tra­tions ­were high­er in eosin­o­phil­ic ­patients ­than in ­healthy sub­jects. Hyper­eo­sin­o­phil­ic ­patients had ­more EG2+ ­cells ­than ­healthy sub­jects, but EG2+ ­rate ­failed to dif­fer­en­tiate HES ­from oth­er hyper­eo­sin­o­phil­ic con­di­tions (p=0.074). More­over, the ­release in ­vitro of ECP and EPX was sig­nif­i­cant­ly high­er in HES ­patients (p<0.05).
Con­clu­sions. Our pre­lim­i­nary ­results ­seem to sug­gest the impor­tance of func­tion­al ­data, ­such as ECP and EPX ­release, in dif­fer­en­tiat­ing HES ­from oth­er hyper­eo­sin­o­phil­ic dis­eas­es. Par­tic­u­lar­ly, ECP and EPX ­release in ­vitro is high­er in ­cell cul­tures ­from HES ­patients ­than ­from ­patients ­with oth­er hyper­eo­sin­o­phil­ic con­di­tions.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail